Javenlin hires former FDA director
Executive Summary
Former FDA Anesthetics, Analgesics & Drug Abuse Division Deputy Director Curtis Wright becomes VP of risk management and regulatory affairs at Javenlin effective immediately. In the newly created post, Wright will oversee health risk assessments, with a focus on abuse associated with pain products, which the company characterized as a growing regulatory concern. Wright will provide risk management oversight for Javenlin's three pain candidates in Phase II development. He joins Javenlin following his June departure from Purdue Pharma, where he worked as exec medical director of clinical risk assessment. Javenlin Pharmaceuticals was known as Intrac prior to Sept. 7...
You may also be interested in...
US FDA Cast As Culpable Player In Opioid Epidemic In Hulu’s Dopesick Series
Show depicts former agency officials approving OxyContin labeling that enabled Purdue to market it as nonaddictive and subsequently refusing pleas to restrict its use.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.